Monica Garcia-Alloza

List of Publications by Year
in descending order

69 papers	6,225 citations	109321 35 h-index	98798 67 g-index
71 all docs	71 docs citations	71 times ranked	8761 citing authors

#	Article	IF	Citations
1	Rapid appearance and local toxicity of amyloid-Î² plaques in a mouse model of Alzheimerâ€™s disease. Nature, 2008, 451, 720-724.	27.8	916
2	Oligomeric amyloid Î² associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4012-4017.	7.1	734
3	Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of Disease, 2006, 24, 516-524.	4.4	633
4	Curcumin labels amyloid pathology inÂvivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. Journal of Neurochemistry, 2007, 102, 1095-1104.	3.9	591
5	Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2146.	12.8	219
6	Cholinergicâ€“serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimerâ€™s disease. Neuropsychologia, 2005, 43, 442-449.	1.6	193
7	Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain, 2007, 130, 2310-2319.	7.6	164
8	Cerebrovascular lesions induce transient Â-amyloid deposition. Brain, 2011, 134, 3697-3707.	7.6	156
9	Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-AÎ² Antibody Administration in PDAPP Mice. Journal of Neuroscience, 2008, 28, 14156-14164.	3.6	136
10	Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease. Neuropsychopharmacology, 2004, 29, 410-416.	5.4	128
11	Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology, 2013, 38, 2462-2475.	2.7	118
12	Lack of localization of 5-HT6receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6receptor-mediated acetylcholine release. European Journal of Neuroscience, 2006, 24, 1299-1306.	2.6	110
13	Detection of isolated cerebrovascular Î²â€amyloid with pittsburgh compound B. Annals of Neurology, 2008, 64, 587-591.	5.3	91
14	Rapid Î²-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice. Journal of Neuropathology and Experimental Neurology, 2013, 72, 272-285.	1.7	91
15	Plaque-Derived Oxidative Stress Mediates Distorted Neurite Trajectories in the Alzheimer Mouse Model. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1082-1089.	1.7	85
16	Central Proliferation and Neurogenesis Is Impaired in Type 2 Diabetes and Prediabetes Animal Models. PLoS ONE, 2014, 9, e89229.	2.5	85
17	Increased AÎ² production prompts the onset of glucose intolerance and insulin resistance. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1373-E1380.	3.5	81
18	Human tau increases amyloid Î² plaque size but not amyloid Î²â€mediated synapse loss in a novel mouse model of Alzheimer's disease. European Journal of Neuroscience, 2016, 44, 3056-3066.	2.6	81

#	Article	IF	Citations
19	Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimerâ€™s disease and type 2 diabetes. Alzheimer's Research and Therapy, 2020, 12, 40.	6.2	77
20	Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease. Journal of Neuroscience, 2006, 26, 365-371.	3.6	69
21	Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neuroscience Letters, 2005, 375, 37-41.	2.1	64
22	Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. Journal of Neurochemistry, 2009, 109, 1636-1647.	3.9	63
23	Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer's disease. Psychoneuroendocrinology, 2015, 62, 69-79.	2.7	57
24	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1110-1117.	3.1	56
25	Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Molecular Neurodegeneration, 2009, 4, 19.	10.8	56
26	Antibody-Mediated Clearance of Amyloid-Â Peptide from Cerebral Amyloid Angiopathy Revealed by Quantitative In Vivo Imaging. Journal of Neuroscience, 2007, 27, 1973-1980.	3.6	55
27	Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2005, 64, 588-594.	1.7	54
28	Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. Psychoneuroendocrinology, 2014, 48, 123-135.	2.7	54
29	Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 3428-3438.	4.0	50
30	Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimerâ€™s disease and type 2 diabetes. Psychoneuroendocrinology, 2016, 65, 15-25.	2.7	49
31	Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2010, 38, 482-491.	4.4	44
32	A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiology of Disease, 2007, 28, 286-292.	4.4	40
33	Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 43-50.	2.6	39
34	Alzheimerâ€™s Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models. Biomolecules, 2021, 11, 262.	4.0	39
35	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 659-668.	2.6	38
36	Specific Serotonergic Denervation Affects tau Pathology and Cognition without Altering Senile Plaques Deposition in APP/PS1 Mice. PLoS ONE, 2013, 8, e79947.	2.5	38

#	Article	IF	Citations
37	Long-Term Mangiferin Extract Treatment Improves Central Pathology and Cognitive Deficits in APP/PS1 Mice. Molecular Neurobiology, 2017, 54, 4696-4704.	4.0	36
38	Effect of Selective Cholinergic Denervation on the Serotonergic System: Implications for Learning and Memory. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1074-1081.	1.7	35
39	GABAA receptor antagonists enhance cortical acetylcholine release induced by 5-HT3 receptor blockade in freely moving rats. Brain Research, 2002, 956, 81-85.	2.2	34
40	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends in Endocrinology and Metabolism, 2022, 33, 50-71.	7.1	34
41	Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. Neurobiology of Aging, 2010, 31, 2058-2068.	3.1	32
42	Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus. Molecular Neurobiology, 2016, 53, 2685-2697.	4.0	32
43	Low-voltage pattern and absence of sleep-wake cycles are associated with severe hemorrhage and death in very preterm infants. European Journal of Pediatrics, 2015, 174, 85-90.	2.7	31
44	Mango leaf extract improves central pathology and cognitive impairment in a type 2 diabetes mouse model. Brain Pathology, 2017, 27, 499-507.	4.1	30
45	Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimerâ€™s Disease and Type 2 Diabetes. Molecular Neurobiology, 2018, 55, 6130-6144.	4.0	30
46	In Vivo Imaging of Microglia With Multiphoton Microscopy. Frontiers in Aging Neuroscience, 2018, 10, 218.	3.4	29
47	Amyloid beta and diabetic pathology cooperatively stimulate cytokine expression in an Alzheimerâ€™s mouse model. Journal of Neuroinflammation, 2020, 17, 38.	7.2	29
48	Techniques for Brain Imaging In Vivo. NeuroMolecular Medicine, 2005, 6, 065-078.	3.4	28
49	Germinal Matrix-Intraventricular Hemorrhage of the Preterm Newborn and Preclinical Models: Inflammatory Considerations. International Journal of Molecular Sciences, 2020, 21, 8343.	4.1	27
50	Selective effects of the APOE Îµ4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiology of Disease, 2006, 22, 555-561.	4.4	26
51	Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats. Psychopharmacology, 2003, 169, 35-41.	3.1	24
52	Review of the Effect of Natural Compounds and Extracts on Neurodegeneration in Animal Models of Diabetes Mellitus. International Journal of Molecular Sciences, 2019, 20, 2533.	4.1	24
53	Cognitive Impairment and Brain and Peripheral Alterations in a Murine Model of Intraventricular Hemorrhage in the Preterm Newborn. Molecular Neurobiology, 2018, 55, 4896-4910.	4.0	19
54	Role of liraglutide in Alzheimerâ€™s disease pathology. Alzheimer's Research and Therapy, 2021, 13, 112.	6.2	18

#	Article	IF	Citations
55	Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation. Neuropharmacology, 2004, 47, 225-232.	4.1	17
56	Intranasal insulin reverts central pathology and cognitive impairment in diabetic mother offspring. Molecular Neurodegeneration, 2017, 12, 57.	10.8	17
57	A novel PKC activating molecule promotes neuroblast differentiation and delivery of newborn neurons in brain injuries. Cell Death and Disease, 2020, 11, 262.	6.3	17
58	Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimerâ€™s Disease and Type 2 Diabetes. Frontiers in Aging Neuroscience, 2021, 13, 741923.	3.4	17
59	Transcriptional correlates of the pathological phenotype in a Huntingtonâ€™s disease mouse model. Scientific Reports, 2019, 9, 18696.	3.3	16
60	Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage. Frontiers in Cell and Developmental Biology, 2020, 8, 571258.	3.7	13
61	Effects of classical PKC activation on hippocampal neurogenesis and cognitive performance: mechanism of action. Neuropsychopharmacology, 2021, 46, 1207-1219.	5.4	13
62	Cell proliferation and neurogenesis alterations in Alzheimerâ€™s disease and diabetes mellitus mixed murine models. Journal of Neurochemistry, 2020, 154, 673-692.	3.9	11
63	Reducing Available Soluble Î²-Amyloid Prevents Progression of Cerebral Amyloid Angiopathy in Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1009-1017.	1.7	9
64	Four-dimensional microglia response to anti-AÎ² treatment in APP/PS1xCX3CR1/GFP mice. Intravital, 2013, 2, e25693.	2.0	7
65	Altered plasma-type gelsolin and amyloid-Î² in neonates with hypoxic-ischaemic encephalopathy under therapeutic hypothermia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1349-1354.	4.3	6
66	Mitochondria-ER contacts and glucose: the powerhouse of Alzheimer's disease?. Cell Calcium, 2021, 97, 102434.	2.4	2
67	Prediabetes and type 2 diabetes implication in central proliferation and neurogenesis. Neural Regeneration Research, 2015, 10, 28.	3.0	2
68	Effect of passive immunotherapy on the rate of progression of cerebral amyloid angiopathy (caa) in transgenic mice. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434-435.	1.7	0
69	EFFECT OF PASSIVE IMMUNOTHERAPY ON THE RATE OF PROGRESSION OF CEREBRAL AMYLOID ANGIOPATHY (CAA) IN TRANSGENIC MICE. FASEB Journal, 2007, 21, A73.	0.5	0